#47 Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
A Harvard neuroscientist has submitted testimony to the D.C. Circuit Court highlighting concerns that federal rescheduling of cannabis without adequate public health safeguards could expose vulnerable populations to documented neurological and developmental risks. The testimony emphasizes that while cannabis has therapeutic potential for certain conditions, accelerating access through rescheduling may outpace the scientific evidence needed to establish safe dosing, formulation standards, and patient selection criteria. This legal intervention underscores the tension between expanding patient access and ensuring clinical safety, particularly regarding effects on adolescent brain development, cognitive function, and mental health outcomes. For clinicians, this argument suggests that rescheduling policy decisions may occur independent of the clinical evidence base needed to guide evidence-based prescribing practices. The practical takeaway is that physicians should advocate for robust clinical guidelines and safety protocols to accompany any regulatory changes, while remaining informed about the current evidence on cannabis risks and benefits to counsel patients appropriately.
“I appreciate that we’re finally having serious conversations about cannabis scheduling at the federal level, but the neuroscientist’s concern reflects what I see in clinical practice: we have legitimate therapeutic signals for specific conditions, yet we’re still working with incomplete safety data on long-term neurological effects, particularly in developing brains. Any policy shift needs to be paired with robust epidemiological surveillance and honest counseling about what we don’t yet know.”
🧠 As the federal rescheduling of cannabis proceeds through the courts, clinicians should recognize that regulatory decisions and scientific evidence about safety do not always align perfectly. While cannabis rescheduling may increase access for patients with legitimate therapeutic needs, the neuroscientist’s concern about incomplete characterization of public health risks—particularly regarding neurodevelopmental effects, cannabis use disorder, and psychiatric outcomes in vulnerable populations—reflects genuine gaps in our clinical knowledge base. The evidence base for cannabis in most conditions remains limited compared to established pharmacotherapies, and dosing, formulation, potency, and individual susceptibility factors are poorly standardized across the market. Rather than waiting for regulatory clarity, clinicians should engage in shared decision-making that acknowledges both potential benefits and documented harms, screen actively for cannabis use disorder and cognitive effects especially in adolescents and young adults, and remain skeptical of claims that rescheduling alone resolves safety questions. A
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
